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Malignant pleural mesothelioma (MPM) is a rare, aggressive cancer caused by asbestos exposure. An
inherited predisposition has been suggested to explain multiple cases in the same family and the
observation that not all individuals highly exposed to asbestos develop the tumor. Germline mutations in
BAP1 are responsible for a rare cancer predisposition syndrome that includes predisposition to meso-
thelioma. We hypothesized that other genes involved in hereditary cancer syndromes could be
responsible for the inherited mesothelioma predisposition. We investigated the prevalence of germline
variants in 94 cancer-predisposing genes in 93 MPM patients with a quantified asbestos exposure. Ten
pathogenic truncating variants (PTVs) were identified in PALB2, BRCA1, FANCI, ATM, SLX4, BRCA2, FANCC,
FANCF, PMS1 and XPC. All these genes are involved in DNA repair pathways, mostly in homologous
recombination repair. Patients carrying PTVs represented 9.7% of the panel and showed lower asbestos
exposure than did all the other patients (p ¼ 0.0015). This suggests that they did not efficiently repair the
DNA damage induced by asbestos and leading to carcinogenesis.
This study shows that germline variants in several genes may increase MPM susceptibility in the
presence of asbestos exposure and may be important for specific treatment.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Traslazionale, Universita del
AOU Maggiore della Carita e
C. Magnani).
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Malignant pleural mesothelioma (MPM) is a rare and aggressive
cancer caused by exposure to a single carcinogen, asbestos [1]. The
frequency of MPM is dramatically higher in asbestos-polluted
areas, as exemplified by the MPM epidemic in the northern Italy
town of Casale Monferrato caused by the presence of an asbestosnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
M. Betti et al. / Cancer Letters 405 (2017) 38e45 39cement factory (1907e1986). In this area, the average annual inci-
dence in 2009e2013 was 51.2 among men and 20.2 among women
(per 100,000, per year), approximately 10 times higher than the
corresponding Italian incidence rates (http://cpo.it/workspace/
files/pleural-mesothelioma-incidence-574400b9b1625.pdf).
Asbestos induces carcinogenesis by directly interfering with
mitotic spindle formation and by inducing chronic inflammation
[2e4] with the production of cytokines and reactive oxygen species
(ROS) by activatedmacrophages. ROS are also generated by the iron
contained in asbestos fibers [5].
As in cases of exposure to other carcinogens, not all individuals
exposed to high level of asbestos develop cancer [6]. This obser-
vation and the reports of families with multiple cases suggest that
an inherited predisposition may play a role, even though common
asbestos exposure must be considered [7e10]. As for other tumors
[11,12], low-risk susceptibility factors have been identified by
GenomeWide Association studies (GWAs) on the germline genome
of MPM patients [13,14].
The occurrence of a dominant inherited predisposition, termed
a ‘high-risk predisposition’, is a well known concept in cancer and
has been clearly demonstrated for several cancer types [15e18].
Themost studied high-risk factor for MPM is inheritedmutations in
BAP1, a tumor suppressor gene that encodes a deubiquitinase
involved in the modulation of transcription and DNA repair [19]. To
date, 79 families inwhich individuals carry one of 65 germline loss-
of-function (LOF) mutations in BAP1 have been identified world-
wide [20e24]. The carriers are at high risk of a number of tumors,
including mesothelioma, cutaneous and uveal melanoma, clear cell
renal carcinoma, and basal cell carcinoma. Patients are also prone to
develop peculiar cutaneous tumors, called melanocytic BAP1-
mutated atypical intradermal tumors (MBAITs), which are consid-
ered to be a marker of BAP1 syndrome [25].
Investigations on mesothelioma cases with germline BAP1 mu-
tations suggest that these patients require asbestos exposure toTable 1
Clinical features of 93 MPM patients.
Clinical features MPM Patients
(N ¼ 93) N (%)
Patients with PT
(N ¼ 9) N (%)
Gender
Male 65 (69.9%) 6 (66.7%)
Female 28 (30.1%) 3 (33.3%)
Histotype
Epithelioid 62 (66.7%) 8 (88.9%)
Biphasic 16 (17.2%) 1 (11.1%)
Sarcomatoid 12 (12.9%) e
Unknown 2 (2.1%) e
Not available 1 (1.1%) e
Asbestos exposure
Occupational 53 (57%) 5 (44.4%)
Para-occupational 17 (18.3%) 3 (33.3%)
Environmental 19 (20.4%) 1 (11.1%)
Household 1 (1.1%) e
Not available 3 (3.2%) e
History of cancer
At least one first-/second-degree
relative with mesothelioma
16 (17.2%) 2 (22.2%)
Not reported 75 (80.6%) 7 (77.8%)
Not available 2 (2.2%) e
Age at diagnosis, years
Mean ± SD 68 ± 12.3^ 73.9 ± 7.2
Survival
1-year (95% CI) 57% (46e67) 25% (4e56)
2-year (95% CI) 30% (20e40) 12% (1e42)
Quantitative asbestos exposure
Mean ± SD 22.8 ± 137.9^^ 3.8 ± 9.5
Mean ± SD (after logarithmic
transformation)
0.9 ± 1.8 0.8 ± 2.3
Abbreviations: PTVs, pathogenic truncating variants; OR, odds ratio; CI, confidence inter
*Patients with PTVs versus Patients without PTVs; ^Not available for 3 patients; ^^Not adevelop mesothelioma and that these tumors most often have an
epithelioid histotype and may be associated with a long survival
[21,26].
The identification of the BAP1 syndrome prompted us to analyze
BAP1 in 18 families with familial MPM or mesothelioma and mel-
anoma. We found germline BAP1 mutations in only two families
[21,22], suggesting that other genes may play a role in the meso-
thelioma predisposition.
We decided to investigate the overall genetic predisposition
conferred by 94 genes associated with cancer in 93 patients with
MPM who lived in areas subjected in the past to high asbestos
exposure. Asbestos exposure was quantitatively evaluated in all
study participants.Materials and methods
Patients and controls
The study included 93 Italian patients with MPM. Diagnosis was made as
described in Betti et al. [22]. Seventy-seven patients were randomly selected from
the previously reported case-control studies [27,28] and were classified as sporadic,
whereas sixteen patients had a family history of mesothelioma. Six familial and five
sporadic patients were studied for mutations in BAP1 and other genes involved in
familial melanoma, and they were found to be mutation-negative [22].
All patients lived in Piedmont (northern Italy) and signed an informed consent
form. The study was approved by the local ethics committee.
Clinical details on gender, age at diagnosis, survival, histotype, asbestos expo-
sure and family history for mesothelioma for all patients were collected from their
oncologist and/or from the Malignant Mesothelioma Registry of the Piedmont Re-
gion (RMM) (Table 1). Information on family history was limited to first- and
second-degree relatives. Information on asbestos exposure at work, at home and in
the general environment was collected by the RMM using a standardized ques-
tionnaire [29], which was administered by trained interviewers. Asbestos exposure
was classified in the following categories: occupational, para-occupational, envi-
ronmental and household, as previously described [21]. Moreover, exposure was
assessed quantitatively by considering the entire exposure history of every study
subject [30]. In brief, an exposure index was computed for each exposure circum-
stance by multiplying frequency, intensity and duration of exposure. The sum of the
indices provided an estimate of life-long cumulative asbestos exposure.Vs Patients without PTVs
(N ¼ 84) N (%)
OR* (95% CI)
59 (70.2%) 0.8 (0.2e3.6)
25 (29.8%) 1 (reference)
54 (64.3%) 4 (0.5e33.6)
15 (17.9%) 1 (ref: biphasic and sarcomatoid)
12 (14.3%)
2 (2.4%)
1 (1.1%)
48 (42.9%) 0.8 (0.2e3.4)
14 (16.7%) 1 (ref: para-occupational,
environmental and household)18 (21.4%)
1 (1.2%)
3 (3.6%)
14 (16.7%)
68 (80.9%)
2 (2.4%)
p (Mann-Whitney test)
67.4 ± 12.6^ 0.13
p (Log rank test)
59% (47e70) 0.25
30% (20e41)
p (Student's t-test)
24.9±145.3^^
1.1 ± 1.6 0.0015
val; SD, standard deviation.
vailable for 3 patients.
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attending clinician's reports, clinical records and a section of the RMM
questionnaire.
The study also included an appropriate control group of 96 Italian subjects.
Seventy-one controls were healthy subjects, whereas twenty-five controls were
hospitalized for non-neoplastic/non-respiratory conditions. One control per patient,
matched for date of birth (±5 years), gender and Piedmont town (Casale Monferrato
or Turin), was randomly selected from case-control studies previously reported by
our group [27,28]. The sample size was chosen to estimate a possible pathogenic
truncating variants (PTVs) prevalence of 1% with a confidence interval width of
100.0% of the point estimate (i.e. from 0 to 8%).
Next-generation sequencing (NGS) and variant validation
Genomic DNA was extracted from peripheral blood using the QIAamp® DNA
Blood Maxi Kit (QIAGEN Inc., Valencia, CA, USA) according to the manufacturer's
protocol.
Targeted next-generation sequencing (NGS) was performed on patient and
control genomic DNAs (gDNA) using the TruSight® Cancer sequencing panel (Illu-
mina Inc., San Diego, CA, USA) which targets 94 genes involved in common and rare
cancer syndromes. In addition, the set includes 284 SNPs found to be associatedwith
cancer through GWAs. Detailed protocols for the library preparation and data ana-
lyses are described in the Supplementary Methods.
Loss of heterozygosity (LOH) analysis in tumor samples was performed using
Sanger sequencing and microsatellite analyses (Table S1). Protein expression was
evaluated by immunohistochemistry (IHC) (Supplementary Methods).
Statistical analyses
To evaluate the association between patients mutational status and clinical
characteristics, i.e., histological type (epithelioid versus others) and asbestos expo-
sure (occupational versus environmental/para-occupational), a binary logistic
regression was performed. The odds ratio (ORs) and the 95% confidence intervals
(95% CIs) were calculated.
A Student's 2-tailed t-test after normalization using logarithmic transformation
was used to compare the mean cumulative asbestos exposure among patients. The
transformationwas used in order to meet the normal distribution assumption of the
variable required to perform the Student's t-test.
The follow-up time was analyzed from the date of diagnosis to the date of death
or the latest follow-up date. Overall survival (OS) was calculated using a Kaplan-
Meier analysis stratified by group, and the OS difference was determined using
the log-rank test.
The 95% confidence interval of the prevalence of PTVs was computed using the
Poisson distribution [31].
A p value  0.05 was considered statistically significant. Statistical analysis was
performed using STATA v12 (Stata Corporation, College Station, TX, USA).
Results
Patient clinical features
The clinical features of the 93 MPM patients are reported in
Table 1. Asbestos exposure was evaluated as occupational, para-
occupational, environmental and household in approximatelyTable 2
PTVs identified in this study.
Gene Transcript Mutation Mutatio
type
ATM NM_000051.3 c.8436delT p.Ser2812fs Deletion
BRCA1 NM_007294.3 c.3001G > T p.Glu1001* Substitu
BRCA2 NM_000059.3 c.6591_6592delTG p.Glu2198Asnfs*4 Deletion
FANCC NM_000136.2 c.1344delC p.Ala448fs Deletion
FANCF NM_022725.3 c.604delC p.Leu202fs Deletion
FANCI NM_001113378.1 c.3846_3850delCACCT p.Ser1282fs*18 Deletion
PALB2 NM_024675.3 c.691A > T p.Lys231* Substitu
PMS1 NM_000534.4 c.1380delT p.Ser460fs Deletion
SLX4 NM_032444.2 c.2819delG p.Gly940fs Deletion
XPC NM_004628 c.524_528delCAAGA p.Thr175fs Deletion
Abbreviations: PTVs, pathogenic truncating variants; FFPE, Formalin-Fixed Paraffin-Emb
recombination repair; MMR, mismatch repair; NER, nucleotide excision repair; na, not av
BRCA2, early-onset breast cancer gene 2; FANCC, Fanconi Anemia Complementation Gr
Complementation Group I; PALB2, partner and localizer of BRCA2; PMS1, postmeiotic segr
pigmentosum, complementation group C.
All changes are heterozygous.57%,18%, 20% and 1% of patients, respectively. No information about
asbestos exposurewas available for three patients (3.2%). The mean
follow-up time of the 93 MPM patients was 1.8 years (SD 2.2).
Seventy-two patients died,12 were alive and 9 patients were lost at
follow-up. At one year from diagnosis, 57% of the patients were
alive, and at two years only 30% of the patients were still alive.Variant detection and characterization
On average, 70% of the mapped NGS reads were on target re-
gions. Most samples had over 93% of reads with coverage above
20x, while themean per-target depth of coverage across all samples
was 215x.
We identified 772 variants, including 12 indels, five nonsense,
402missense and 353 synonymous variants. Only ten variants were
considered PTVs and were subjected to further study (Table 2). Two
in-frame deletions and eleven missense variants fulfilled the filter
criteria described in Supplementary Methods, and they are re-
ported in Table 3.
All the PTVs, the in-frame deletions and the missense variants
were successfully validated with Sanger sequencing on DNA ob-
tained from peripheral blood.Pathogenic truncating variants
Nine MPM patients (9.7%) harbored heterozygous PTVs in the
following ten genes: PALB2, BRCA1, FANCI, ATM, SLX4, BRCA2, FANCC,
FANCF, PMS1 and XPC (Table 4).
One patient was a double heterozygote for two truncating mu-
tations in different genes: a nonsense mutation in BRCA1
(c.3001G > T p.Glu1001*) and a frameshift mutation in FANCI
(c.3846_3850delCACCT p.Ser1282fs*18).
A nonsense mutation in PALB2 (c.691A > T p.Lys231*) was car-
ried by another patient, whereas frameshift deletions were carried
by seven patients, affecting BRCA2 (c.6591_6592delTG
p.Glu2198Asnfs*4), ATM (c.8436delT p.Ser2812fs), SLX4 (c.2819delG
p.Gly940fs), PMS1 (c.1380delT p.Ser460fs), FANCC (c.1344delC
p.Ala448fs), FANCF (c.604delC p.Leu202fs) and XPC (c.524_528del-
CAAGA p.Thr175fs).
We assessed whether these PTVs were reported in gene- or
disease-databases. Only two PTVs were reported and classified as
pathogenic, i.e. the nonsense mutation in BRCA1 (c.3001G > T
p.Glu1001*) and the frameshift mutation in BRCA2
(c.6591_6592delTG p.Glu2198Asnfs*4) (Table S2).n Mutation
effect
FFPE tumor sample DNA repair
pathway
Frameshift LOH-nuclear protein expression (IHC) HRR
tion Nonsense Cytoplasmatic protein expression (IHC) HRR
Frameshift LOH HRR
Frameshift na HRR
Frameshift na HRR
Frameshift na HRR
tion Nonsense na HRR
Frameshift na MMR
Frameshift Cytoplasmatic protein expression (IHC) HRR
Frameshift na NER
edded; IHC, immunohistochemistry; LOH, loss of heterozygosity; HRR, homologous
ailable; ATM, ataxia telangiectasia mutated; BRCA1, early-onset breast cancer gene 1;
oup C; FANCF, Fanconi Anemia Complementation Group F; FANCI, Fanconi Anemia
egation increased 1; SLX4, Structure-Specific Endonuclease Subunit; XPC, Xeroderma
Table 4
Clinical features of patients carrying PTVs.
Patient ID PTV Gender Histotype Age at onset,
years
Age at death,
years
Asbestos exposure Cancers in relatives
MPM125AL PALB2 c.691A > T p.Lys231* M Biphasic 82 83 Para-occupational Intestinal cancer (brother)
MPM156AL BRCA1 c.3001G > T p.Glu1001*
FANCI c.3846_3850delCACCT p.Ser1282fs*18
F Epithelioid 70 na Occupational Breast cancer (sister)
MPM1115 ATM c.8436delT p.Ser2812fs M Epithelioid 72 75 Occupational nr
MPM1135 SLX4 c.2819delG p.Gly940fs F Epithelioid 64 65 Para-occupational MPM (sister), lung
cancer (mother, father)
MPM88TO BRCA2 c.6591_6592delTG p.Glu2198Asnfs*4 M Epithelioid 65 68 Occupational nr
MPM85AL FANCC c.1344delC p.Ala448fs F Epithelioid 79 79 Para-occupational nr
MPM122AL FANCF c.604delC p.Leu202fs M Epithelioid 81 81 Occupational nr
MPM87TO PMS1 c.1380delT p.Ser460fs M Epithelioid 67 68 Occupational nr
MPM155AL XPC c.524_528delCAAGA p.Thr175fs M Epithelioid 80 82 Environmental MM (mother)
Abbreviations: PTVs, pathogenic truncating variants; M, male; F, female; MM, malignant mesothelioma; MPM, malignant pleural mesothelioma; na, not available; nr, not
reported.
Table 3
Variants of unknown significance (VUS) identified in this study that fulfilled the filter criteria.
Gene Transcript Variant Variant type Variant effect
FANCA NM_000135.2 c.1874G > C p.Cys625Ser Substitution Missense
FANCA NM_000135.2 c.3665C > T p.Pro1222Leu Substitution Missense
FANCA NM_000135.2 c.1255T > G p.Phe419Val Substitution Missense
HNF1A NM_000545.5 c.1226C > A p.Pro409His Substitution Missense
MLH1 NM_000249.3 c.1852_1853delAAinsGC p.Lys618Ala Substitution Missense
MLH1 NM_000249.3 c.1136A > G p.Tyr379Cys Substitution Missense
MSH6 NM_000179.2 c.3727A > T p.Thr1243Ser Substitution Missense
MUTYH NM_001048171.1 c.1145G > A p.Gly382Asp Substitution Missense
TSC2 NM_000548.3 c.1915C > T p.Arg639Trp Substitution Missense
TSC2 NM_000548.3 c.2278A > C p.Thr760Pro Substitution Missense
FANCM NM_020937.2 c.1313_1318delATAAAA p.Asp438_Asn440del Deletion In-frame
ERCC3 NM_000122.1 c.786_791delAGAAGA p.Glu262_Glu264del Deletion In-frame
Abbreviations: FANCA, Fanconi Anemia Complementation Group A; HNF1A, Hepatocyte Nuclear Factor 1-Alpha; MLH1, MutL Homolog 1; MSH6, mutS homolog 6; MUTYH,
MutY DNA Glycosylase; TSC2, Tuberous Sclerosis Complex 2; FANCM, Fanconi Anemia Complementation Group M; ERCC3, ERCC excision repair 3, TFIIH core complex helicase
subunit.
All changes are heterozygous.
M. Betti et al. / Cancer Letters 405 (2017) 38e45 41We also checked the PTV frequencies in public population da-
tabases, on the hypothesis that pathogenic mutations are very rare.
Only the deleterious mutation in FANCI (c.3846_3850delCACCT
p.Ser1282fs*18) is reported in ExAC with an MAF (minor allele
frequency) lower than 0.001% (Table S2). The MAF of each PTV in
our dataset was higher than the MAF of all LOF variants in the
corresponding gene reported by ExAC and EVS databases (p < 0.05).
These investigations, performed on databases including thousands
of subjects, confirmed that these PTVs are very rare in these genes.
When we looked at all the LOF variants in the ten genes in
controls, only one control was found to carry a frameshift mutation
in BRCA2 (different from that carried by our MPM patient), but no
further information (e.g. vital status, cause of death) is available.
Since clinical phenotype is not shared in the population data-
bases, we also evaluated an appropriate control panel of 96 Pied-
mont subjects. No PTVswere found in our control panel, supporting
a PTV role in mesothelioma risk. The 95% confidence interval of the
prevalence of PTVs in controls was from 0 to 3.8%.
The clinical data for the patients are reported in Table 4. Patients
with SLX4 and XPC PTVs had familiarity for mesothelioma in first-
or second-degree relatives, whereas the patient with BRCA1 and
FANCI PTVs had familiarity for breast cancer, and the patient with
PALB2 PTV for intestinal cancer.
Functional studies on tumor samples
Cancer-predisposing genes are most often tumor suppressor
genes whose bi-allelic loss is due to an additional somatic variant in
the tumor that complements the inherited LOF variant.To evaluate the expression of the protein in an FFPE (Formalin-
Fixed Paraffin-Embedded) tumor sample, IHC was performed using
specific antibodies.
IHC using the anti-BRCA1 antibody on an FFPE tumor sample of
MPM156AL showed a diffuse cytoplasmatic staining instead of the
expected nuclear staining (data not shown). Since the inherited
variant was a PTV, the results suggest that a second mutation leads
to a variant non-functional protein. This patient also carried a PTV
in FANCI that was found in tumor DNA, but the FFPE tumor spec-
imen amount was not enough to perform IHC.
The patient who carried a PTV in BRCA2 showed LOH for the
D13S1701 microsatellite marker and a decreased amount of the
D13S171 allele in the FFPE tumor sample (data not shown). This
suggests that a somatic event causes loss of the gene and abolishes
the protein.
The patient who carried a PTV in SLX4 validated in tumor DNA
showed cytoplasmatic positivity in the FFPE tumor sample instead
of the expected nuclear staining, suggesting the presence of a
second somatic variant leading to the production of a non-
functional protein.
The patient with a PTV in ATM showed a decreased amount of
an allele for the sole informative microsatellite marker
(D11S1778) in the tumor DNA (data not shown), suggesting LOH.
However, IHC with the anti-ATM antibody showed normal nu-
clear staining (data not shown), suggesting the presence of a wild
type allele. Since we did not identify the PTV in the tumor tissue,
overall, this result suggests that the mutated allele was lost in the
tumor. This behavior has also been reported for breast cancers
harboring ATM PTVs [32], possibly because during cancer
M. Betti et al. / Cancer Letters 405 (2017) 38e4542progression, allele deletion was more advantageous than the
original PTV.
No tumor specimenwas available from the patients with PTVs in
PALB2, XPC, FANCC, FANCF and PMS1.
Variants of unknown significance (VUS)
Two in-frame deletions and eleven missense variants that ful-
filled the filter criteria were found in eight different genes: ERCC3,
FANCM, FANCA, MLH1, MSH6, MUTYH, TSC2 and HNF1A (Table 3).
The two in-frame deletions (FANCM c.1313_1318delATAAAA
p.Asp438_Asn440del; ERCC3 c.786_791delAGAAGA p.Glu262_-
Glu264del) were carried by a single patient.
Two variants were identified in MLH1. One patient carried the
c.1136A > G p.Tyr379Cys variant, whereas two other patients car-
ried a variant that affects two consecutive base pairs in cis leading
to a Lys618Ala missense variant (c.1852_1853delAAinsGC) already
reported as a VUS in genomic databases (Table S3).
The variants HNF1A c.1226C > A p.Pro409His and MSH6
c.3727A > T p.Thr1243Ser were found in two and one patients,
respectively.
Three variants were found in FANCA (c.1874G > C p.Cys625Ser,
c.3665C > T p.Pro1222Leu, c.1255T > G p.Phe419Val) in four pa-
tients. One of them also carried a TSC2 variant (c.1915C > T
p.Arg639Trp). Another missense variant in TSC2 (c.2278A > C
p.Thr760Pro) was carried by a different patient.Table 5
Clinical features of patients carrying VUS.
Patient ID Variant Gender Histotype Age at
years
MPM1114 FANCA c.1874G > C
p.Cys625Ser
M Biphasic 67
MPM124AL FANCA c.1874G > C
p.Cys625Ser
M Epithelioid 84
MPM1110 FANCA c.1255T > G
p.Phe419Val
M Epithelioid 70
MPM99AL FANCA c.3665C > T
p.Pro1222Leu
TSC2 c.1915C > T
p.Arg639Trp
M Biphasic 80
MPM1119 HNF1A c.1226C > A
p.Pro409His
M Epithelioid 50
MPM82TO HNF1A c.1226C > A
p.Pro409His
M Sarcomatoid 69
MPM173AL MLH1
c.1852_1853delAAinsGC
p.Lys618Ala
M Sarcomatoid na
MPM1120 MLH1
c.1852_1853delAAinsGC
p.Lys618Ala
M Biphasic 69
MPM1129 MLH1 c.1136A > G
p.Tyr379Cys
M Epithelioid 59
MPM94TO MSH6 c.3727A > T
p.Thr1243Ser
M Biphasic 69
MPM97TO MUTYH c.1145G > A
p.Gly382Asp
M Epithelioid 66
MPM126AL MUTYH c.1145G > A
p.Gly382Asp
M Biphasic 74
MPM1135 MUTYH c.1145G > A
p.Gly382Asp
F Epithelioid 64
MPM1132 TSC2 c.2278A > C
p.Thr760Pro
M Epithelioid 58
MPM82AL FANCM
c.1313_1318delATAAAA
p.Asp438_Asn440del
ERCC3
c.786_791delAGAAGA
p.Glu262_Glu264del
M Biphasic 71
Abbreviations: VUS, variants of unknown significance; M, male; F, female; MPM, malignLOF mutations in TSC1 and TSC2 are the cause of tuberous
sclerosis syndrome (TS), a generally severe genodermatosis
inherited as an autosomal dominant trait and characterized by
mental retardation, seizures and angiofibromas of the skin. The
c.1915C > T p.Arg639Trp variant is reported as pathogenic in the TS
database-Leiden Open Variation Database. We cannot rule out that
these patients were affected by TS since information about con-
current inherited disease was not reported in the Registry and
during the interview. It is intriguing that one patient with TS has
been reported to develop a primary pericardial mesothelioma [33].
Moreover, TSC1 has been found to be somatically mutated in me-
sothelioma, and mice with TSC1 and TP53 mutations develop me-
sothelioma [34].
We assessed whether these VUS were reported in gene- or
disease-databases. Only one of the missense variants (MUTYH
c.1145G > A p.Gly382Asp), carried by three patients, is considered
pathogenic in the ClinVar database (Table S3). One of these patients
also carried a PTV in SLX4.
In the population databases, the VUS showed anMAF lower than
0.001 (Table S3). In our control panel, only the two missense
variants, HNF1A c.1226C > A p.Pro409His and MLH1
c.1852_1853delAAinsGC p.Lys618Ala were found, each mutation in
one control (prevalence 1.04%, 95% CI from 0.03 to 5.80%).
The clinical features of the patients are reported in Table 5. Pa-
tients with two missense variants (MUTYH c.1145G > A
p.Gly382Asp; MLH1 p.Lys618Ala) respectively had familiarity foronset, Age at death,
years
Asbestos
exposure
Cancers in relatives
68 Environmental Rectal cancer (father)
84 Para-occupational nr
71 Occupational nr
81 Environmental Breast cancer (mother)
51 Environmental Colon cancer (mother)
70 Occupational nr
na Occupational MPM (father), ovarian
cancer (mother),
lung cancer (paternal uncle)
70 Occupational nr
63 Occupational nr
70 Occupational nr
68 Occupational MPM (paternal cousin),
bone sarcome (sibling)
75 Occupational nr
65 Para-occupational MPM (sister), lung cancer
(mother, father)
e Occupational Lung cancer (father), cancer
of unknown
site (son)
71 Para-occupational nr
ant pleural mesothelioma; nr, not reported; na, not available.
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cancers was found in patients with FANCA, HNF1A and TSC2
variants.
Because the data are not unequivocal, all these variants should
be considered VUS until their effect is evaluated by segregation and
functional studies.
Other findings
A group of variants that did not fulfill the selected filter criteria
are nevertheless mentioned here because they have been reported
as low-risk factors in the literature.
MITF c.952G > A p.Glu318Lys (rs149617956), which is consid-
ered a low-risk factor for familial melanoma [35], was found in a
single MPM patient who also carried MUTYH c.1145G > A
p.Gly382Asp.
We also found a BAP1missense variant (c.944A > C p.Glu315Ala)
(rs149974450) in one patient. This variant is reported in ExAC and
EVS with an MAF lower than 0.02%, but four out of six in silico
prediction tools considered it as benign. A functional assay is
needed to evaluate the effect of this VUS.
Statistical analyses
Patients were divided into three groups, i.e. patients carrying
PTVs, patients carrying VUS and patients who were non-carriers
(i.e. patients who did not carry either PTV or VUS). Statistical an-
alyses were performed to evaluate the differences among these
groups (Table 1, Tables S4 and S5).
The mean of the quantitative asbestos exposure was 3.8 (SD 9.5)
for the group with PTVs and 24.9 (SD 145.3) for the group without
PTVs. A statistically significant difference of the mean values of
quantitative exposure between these two groups was detected
(p ¼ 0.0015) (Table 1). A statistically significant difference was also
present when the quantitative exposure of the PTV group was
compared with either the 70 non-carrier patients (p ¼ 0.0039)
(Table S4) or the VUS group (p ¼ 0.008) (Table S5a). No statistically
significant difference of the mean value of quantitative exposure
was found when the 14 patients with VUS were compared with the
70 non-carrier patients (p ¼ 0.38, Table S5b).
No statistically significant associationwas found for histotype or
the categories of asbestos exposure in the groups with and without
PTVs. Considering the groupwithout PTVs as a reference, the OR for
patients with sarcomatoid and biphasic histologies compared with
those who had epithelioid histology was 4 (95% CI 0.5e33.6), and
the OR among those with occupational exposure compared with
those with environmental, para-occupational and household
asbestos exposure was 0.8 (95% CI 0.2e3.4) (Table 1). The mean age
at diagnosis was 73.9 (SD 7.2) for the group with PTVs and 67.4 (SD
12.6) for the other group. No significant differences in age at
diagnosis or survival were found between the two groups (p ¼ 0.13
and p ¼ 0.25, respectively) (Table 1).
Discussion
Our study shows, for the first time, that a substantial proportion
(9.7%) of MPM patients carry PTVs in DNA repair genes, and that
these patients show a statistically significant lower intensity of
asbestos exposure. This suggests that although asbestos exposure is
necessary to developMPM, in these patients even a low exposure to
asbestos is sufficient to induce tumorigenesis.
Interestingly, eight of these mutated genes are involved in ho-
mologous recombination repair (HRR) (BRCA1, BRCA2, PALB2, ATM,
FANCI, FANCC, FANCF, SLX4), like BAP1, whereas two (XPC and PMS1)
are involved in nucleotide excision repair (NER) and mismatchrepair (MMR), respectively. HRR is the mechanism used to repair
double-strand breaks (DSBs) induced by asbestos fibers. On the
other hand, asbestos may also cause DNA damage repaired by base
excision repair (BER), NER or MMR.
It is thus possible to hypothesize that these patients, because of
their defect in DNA repair, were less able to repair DNA damage
induced by asbestos.
Moreover, 14 patients (15%) carried rare missense and in-frame
variants considered damaging by in silico prediction tools and
located in FANCA, TSC2, HNF1A, MLH1, MSH6, MUTYH, ERCC3 and
FANCM. Although a stringent approach cannot consider these mu-
tations as pathogenic without functional analyses, it is intriguing to
note that they are located in genes involved in the same DNA repair
pathways reported for the PTVs, i.e. HRR (FANCA, FANCM), NER
(ERCC3) and MMR (MLH1, MSH6, MUTYH).
Our approach of variant classification was very conservative,
sincewe did not consider the possible pathogenicmissense variants
in the analysis. Consequently, we may have underestimated the
prevalence of mutation carriers. Moreover, the NGS approach that
we used does not reveal large rearrangements, for which a whole
genome NGS or CGH-based approach would be more appropriate
[36,37]. Last and not least, mutations in genes that are not included
in the TruSight Cancer panel were not screened. Thus, it is possible
that patients who did not carry variants in the 94 genes that were
the object of our study harbor variants in genes that were not
screened. In order to completely characterize all genes conferring
increased risk of MPM, a whole exome approach is needed.
Our data show, for the first time, that predisposition to MPM is
very heterogeneous, similar to that reported for pancreatic cancer
and other cancer types [17,18,38]. Also the proportion of patients
carrying PTV is similar.
Our study suggests that MPM could be added to the constella-
tion of tumors resulting from mutations in BRCA1, BRCA2, ATM,
SLX4, FANCC, FANCI, PALB2, FANCF, PMS1 and XPC. Most probably the
type of carcinogen exposure is relevant for the cancer type that will
be developed by variant carriers, as suggested for BAP1 [21].
The characterization of mutation carriers within these families
is of particular clinical importance because all carriers are at risk for
a certain cancer spectrum and should be included in specific high-
risk surveillance and secondary prevention programs [39]. Finally,
identification of inherited predisposition for mesothelioma may
prove to be important for treatment in the future. This was the case
of ovarian cancers due to predisposing germline BRCA1 and BRCA2
variants, where a different response to PARP inhibitors was iden-
tified [40,41]. Similarly, the identification of subsets of patients who
carry predisposing mutations in the homologous recombination
pathway may distinguish patients who can benefit from drugs that
induce synthetic lethality [42,43].
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